Investment and Collaboration Agreement by and between BioLineRx Ltd. and Novartis Pharma AG December 16, 2014Investment and Collaboration Agreement • March 23rd, 2015 • BioLineRx Ltd. • Pharmaceutical preparations • New York
This Investment and Collaboration Agreement (the “Agreement”) is entered into as of December 16, 2014 (the “Effective Date”) by and between Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland and having its principal place of business at Lichtstrasse 35, CH-4056, Basel, Switzerland (“NVS”), and BioLineRx Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, Jerusalem, 91450, Israel (“BioLine”).
KalVista Get a Notable Investment and Collaboration AgreementInvestment and Collaboration Agreement • October 16th, 2017
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body's inflammatory response and which, in excess, can lead to increased vascular permeability, edema, and inflammation.
